Results 101 to 110 of about 165,865 (302)

Consideraciones actuales sobre el diagnóstico y tratamiento del cáncer tiroideo

Revista Cubana de Medicina Militar, 2022
Introducción: Desde los inicios de este siglo se ha producido un notable incremento mundial de la tasa de incidencia del cáncer de tiroides, el cual generalmente tiene un curso larvado y asintomático.
Ramiro Julio Bejerano, Héctor Manuel Camué Ciria   +1 more
doaj  

Activation of proto-oncogenes by disruption of chromosome neighborhoods

, 2016
Oncogenes are activated through well-known chromosomal alterations such as gene fusion, translocation, and focal amplification. In light of recent evidence that the control of key genes depends on chromosome structures called insulated neighborhoods, we ...
Weintraub, Abraham Selby, Fan, Zi Peng, Li, Charles, Lajoie, Bryan R., Sigova, A. A., Young, Richard A., Dekker, J., Porteus, Matthew, Young, Richard, Sigova, Alla A., Li, Charles Han, Day, Daniel S., Li, Charles H., Day, Daniel, Porteus, Matthew H., Weintraub, Abraham, Jaenisch, Rudolf, Day, D. S., Weintraub, Abraham S., Lajoie, Bryan, Sigova, Alla, Borges-Rivera, Diego, Bak, R. O., Borges-Rivera, Diego Ramon, Valton, Anne-Laure, Valton, A.-L., Lee, Tong Ihn, Lajoie, B. R., Lee, T. I., Porteus, M. H., Dekker, Job, Reddy, Jessica, Goldmann, J., Goldmann, Johanna, Bak, Rasmus O., Hnisz, Denes, Bak, Rasmus, Hnisz, D.   +37 more
core   +1 more source

ZW4864‐mediated inhibition of the β‐catenin/BCL9/BCL9L complex reveals therapeutic potential in bladder cancer

Molecular Oncology, EarlyView.
BCL9 and BCL9L drive bladder cancer progression by enhancing β‐catenin signaling, promoting proliferation, migration, invasion, and organoid growth. Genetic depletion of BCL9(L) suppresses malignant phenotypes, while pharmacological disruption of the β‐catenin/BCL9(L) complex with ZW4864 inhibits canonical Wnt signaling and tumor‐associated cellular ...
Roland Kotolloshi, Mandy Berndt‐Paetz, Eileen Lerner, Gregoire Najjar, Anca Azoitei, Krishna Pal Singh, Shailendra Kumar Gupta, Olaf Wolkenhauer, Cagatay Günes, Otmar Huber, Marc‐Oliver Grimm, Daniel Steinbach   +11 more
wiley   +1 more source

Oncogenes of DNA and RNA tumor viruses and the origin of cellular oncogenes.

, 1993
Oncogenes were first described as the genes of DNA tumor viruses responsible for in vivo and in vitro neoplastic transformation induced by such viruses. The first oncogenes described were the oncogenes of polyoma, SV40 and papilloma viruses.
VECCHIO, GIANCARLO
core  

Evaluación del estado de amplificación de oncogenes, como marcadores moleculares en DNA libre en plasma de pacientes con cáncer pulmonar [PDF]

, 2014
En el cáncer se presentan distintos cambios en el genoma, la amplificación de oncogenes se ha descrito como una de las más frecuentes. Conocer la biología molecular del cáncer e identificar cambios moleculares comunes en la heterogeneidad del cáncer ...
Cruz Lozano, Yara
core  

Specific Targeting of Oncogenes Using CRISPR Technology

, 2018
Oppel F, Schürmann M, Goon P, Albers AE, Sudhoff H. Specific Targeting of Oncogenes Using CRISPR Technology. Cancer Research.
Schürmann, Matthias, Sudhoff, Holger ; https://orcid.org/, Oppel, Felix, Goon, Peter, Albers, Andreas E.   +4 more
core   +1 more source

Identifying transcription factors controlling the basal expression of human MRP4 highlights a substantial role for Sp1

FEBS Open Bio, EarlyView.
The MRP4 transporter exports several drugs and signaling molecules. Here, we identified key promoter elements regulating basal MRP4 expression. Using reporter assays, we defined a conserved region with essential Sp1 and contributory Ets sites, which controlled basal MRP4 expression.
Debora Singer, Angelique Kragl, Katrin Ziems, Juliane Glaubitz, Sophie Grammbauer, Susanne Hildebrandt, Mladen V. Tzvetkov, Gabriele Jedlitschky   +7 more
wiley   +1 more source

Evidence that synthetic lethality underlies the mutual exclusivity of oncogenic KRAS and EGFR mutations in lung adenocarcinoma

eLife, 2015
Human lung adenocarcinomas (LUAD) contain mutations in EGFR in ∼15% of cases and in KRAS in ∼30%, yet no individual adenocarcinoma appears to carry activating mutations in both genes, a finding we have confirmed by re-analysis of data from over 600 LUAD.
Arun M Unni, William W Lockwood, Kreshnik Zejnullahu, Shih-Queen Lee-Lin, Harold Varmus   +4 more
doaj   +1 more source

Emerging insights into CC and CXC chemokines and their receptors in Mycobacterium tuberculosis infection

FEBS Open Bio, EarlyView.
The dual roles of CC and CXC chemokines in distinguishing active, latent, and subclinical tuberculosis were reviewed, along with an evaluation of their potential as diagnostic biomarkers and therapeutic targets to advance precision medicine in tuberculosis management. The graphical abstract was generated with AI assistance (Gemini 3.0).
Xuying Yin, Dangsheng Xiao, Jiezuan Yang
wiley   +1 more source

Enrichment of oncogenes during the early time points.

, 2013
All upregulated DE genes at each time point (when compared to the zero hour control) were interrogated for being oncogenes by their presence in the Memorial Sloan Kettering Cancer Center Oncogene set (http://cbio.mskcc.org/CancerGenes/Select.action) and ...
Chris Barry (374156), Cynthia Alexander Rascón (386638), Jennifer M. Bolin (386644), Jeff Nie (5707), Hamisha Ardalani (386641), Ning Leng (386645), Mitchell D. Probasco (386643), Li-Fang Chu (386640), Ron Stewart (114673), Ryan J. Wagner (386642), Michael Volkmer (4850), Shulan Tian (386639), Srikumar Sengupta (259261), James A. Thomson (386646), Bianca Habermann (4847), Colin N. Dewey (257084), Elly M. Tanaka (228562)   +16 more
core   +1 more source